elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26829152-6C5ACC02-F784-4E44-969E-5003CC3F080B
Q26829152-6C5ACC02-F784-4E44-969E-5003CC3F080B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26829152-6C5ACC02-F784-4E44-969E-5003CC3F080B
Emerging pharmacologic treatment options for fragile X syndrome
P2860
Q26829152-6C5ACC02-F784-4E44-969E-5003CC3F080B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26829152-6C5ACC02-F784-4E44-969E-5003CC3F080B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
fa9673a6f1e91a6a617a959d9d7aadc59a4f41f9
P2860
Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.